Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 25, 2008 Brian Orelli	An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets.
The Motley Fool July 18, 2008 Rich Duprey	More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry.
The Motley Fool February 29, 2008 Brian Orelli	Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006.
The Motley Fool May 12, 2008 Brian Orelli	Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations.
The Motley Fool August 9, 2007 Brian Orelli	Acquisition Raises Barr Half a year after acquiring a giant competitor, Barr Pharmaceuticals results appear to be on track to increase year-over-year revenues.
The Motley Fool July 28, 2009 Brian Orelli	All Growth, All the Time This generic-drug maker is no value play.
The Motley Fool March 5, 2008 Brian Orelli	Yasmin Raises the Revenue Barr Barr gets a patent on Bayer's Yasmin overturned.
The Motley Fool February 7, 2006 Stephen D. Simpson	Barr None Bargain hunters are probably going to come up short when it comes to assessing Barr Pharmaceuticals' stock, but a fairly rich package of opportunities should keep growth strong for the immediate future.
The Motley Fool November 8, 2006 Brian Lawler	Barr's Wounded Quarter If your revenues live by the generic sword, they can die by it, too. That seems to be the case today for Barr Pharmaceuticals. Investors, take note.
The Motley Fool May 28, 2008 Brian Orelli	A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most.
The Motley Fool September 8, 2005 Stephen D. Simpson	Raising the Barr This large generics company sees better margins and an optimistic outlook. The company has a top-notch return on assets and a valuation that, while not cheap, isn't ridiculous either.
The Motley Fool May 14, 2007 Brian Lawler	Mylan Goes on a Drug Binge The generic drugmaker makes a hefty acquisition, but it's hard to say at this point how good of a deal this is for shareholders.
The Motley Fool May 4, 2006 Stephen D. Simpson	A More Realistic Bar for Barr Labs An unpleasant, but not altogether unexpected drop makes this generic drug company and better value for investors.
The Motley Fool February 18, 2009 Brian Orelli	Teva Raises the Barr Generic drugs are likely to be a major solution that governments use to tackle the problem of rising health-care costs, and the new, larger Teva looks well-poised to grab that growth as it happens.
The Motley Fool September 4, 2008 Brian Orelli	Tapping the Brakes on the Teva-Barr Deal The FTC wants more information on this pharma merger before it offers its approval.
The Motley Fool November 26, 2008 Brian Orelli	Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better."
The Motley Fool September 11, 2006 Brian Lawler	Barr's Bidding War Barr Pharmaceuticals takes a big bite of the booming generics market. Investors, take note.
The Motley Fool February 28, 2007 Brian Lawler	Worrisome Watson The maker of generic drugs could have a challenging year ahead. Investors, take note.
The Motley Fool June 27, 2006 Stephen D. Simpson	Barr Bulks Up For Barr Labs, buying Pliva adds manufacturing capabilities, market opportunities, and pipeline candidates. Investors, take note.
The Motley Fool September 19, 2006 Brian Lawler	Barr's Winning Bid The pharmaceutical wins its tug-of-war for generic drug firm Pliva. Investors would be smart to watch for any potential teething problems from the much larger and busier Barr.
The Motley Fool December 17, 2007 Brian Orelli	Barr Labs' Legal Tables Turned Barr Labs announces that is suing both Watson Pharmaceuticals and Novartis' generic subsidiary Sandoz for patent infringement regarding Barr's SEASONALE extended-cycle birth control pill.
The Motley Fool February 23, 2007 Rich Duprey	Foolish Forecast: Barr Labs Resets Bar The pharmaceutical is set to release fourth-quarter 2006 financial results. Investors, here is what you can expect to see.
The Motley Fool June 27, 2008 Brian Orelli	Barr's Lawyers Earn Their Keep Generic-drug maker Barr Pharmaceutical gets another patent thrown out.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool August 15, 2006 Stephen D. Simpson	Twirling the Barr Look closely and you'll see that Barr posted a solid quarter. Investors, if you haven't checked this one out yet, now may be the time for a little due diligence.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool December 28, 2006 Brian Lawler	Pliva's Late Christmas Gift to Barr Normally generic drug competitors, Barr Pharmaceuticals and Par Pharmaceutical Companies announced the launch of a generic version of GlaxoSmithKline's drug, Zofran. Investors, take note.
The Motley Fool November 1, 2005 Stephen D. Simpson	Belly Up to Barr Though not cheap, this is a high-quality generic drug company. However, investors must do their own due diligence and decide for themselves whether today's price offers enough margin of safety for a sound investment.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool June 30, 2006 Stephen D. Simpson	Barr Labs and Pliva: Round 2 The Croatian generic drugmaker is now a hot property, as a previously spurned bidder, Icelandic generics firm Actavis, refuses to let Barr Labs win this battle yet. Investors, take note.
The Motley Fool June 27, 2007 Billy Fisher	Improving Morale at Barr Preliminary OK of Barr Pharmaceutical's generic antidepressant perks up the stock's potential.
BusinessWeek April 15, 2010 Naomi Kresge	As the Pill Turns 50, a Rivalry Heats Up With underserved markets in Asia beckoning, Teva is taking on Bayer, the leader in oral contraceptives
The Motley Fool November 3, 2009 Brian Orelli	Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call.
The Motley Fool November 10, 2006 Brian Lawler	Watson Doesn't Wow Investors The generic drug developer made a $2 billion buyout of smaller competitor Andrx and finally closed the deal this quarter. Investors, take note.
The Motley Fool November 12, 2007 Brian Orelli	Raising the Barr Barr Pharmaceuticals' acquisition of Pliva increases sales, but it doesn't help raise the bottom line. Investors, take note.
The Motley Fool August 3, 2007 Brian Orelli	Watson Turns It Around The pharmaceutical's steady revenue growth results in positive income for the quarter. Investors, take note.
The Motley Fool May 5, 2009 Brian Orelli	Generic Growth, Acquisition Style Sales at Teva Pharmaceuticals were up 22% year over year, but don't bust out the champagne just yet.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool September 25, 2008 Brian Orelli	Teva Heads to Japan It's conquering the world, slowly but surely. But is it still a value play?
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
The Motley Fool February 28, 2007 Brian Lawler	Barr's Becoming Big Generic drug producer Barr Pharmaceuticals announces its first quarterly earnings numbers after acquiring Pliva. Investors, take note.
The Motley Fool July 25, 2005 Stephen D. Simpson	Teva Tries to Buy Back the Top Spot $7.4 billion later, Teva Pharmaceuticals is poised to become the largest generics company in the world once again. Investors, take note.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool March 13, 2006 Stephen D. Simpson	Watson Pays Up to Stay in the Game Watson gets bigger, but how much better? The company is buying Andrx for $25 a share. Investors, take note.
The Motley Fool March 19, 2009 Brian Orelli	Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too.
The Motley Fool November 5, 2004 Roger Nusbaum	The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy.
Chemistry World October 8, 2012 Phillip Broadwith	Europe gives generics merger the green flag Two of the top five global generic medicines manufactures, Watson and Actavis, have been given the go-ahead to merge by the European Commission.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.